Gilead Sciences (GILD) Tops Q3 EPS by 33c, Updates FY15 Guidance

Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $3.22, $0.33 better than the analyst estimate of $2.89. Revenue for the quarter came in at $8.3 billion versus the consensus estimate of $7.82 billion.

Product Sales

Total product sales for the third quarter of 2015 were $8.2 billion compared to $6.0 billion for the third quarter of 2014. Product sales in the U.S. were $5.6 billion compared to $4.2 billion for the third quarter of 2014. In Europe, product sales were $1.7 billion compared to $1.4 billion for the same period in 2014. Sales in other international locations increased to $1.0 billion compared to $327 million in the third quarter of 2014 primarily as a result of the launch of our HCV products in Japan.

Gilead Sciences sees FY2015 revenue of $30-31 billion, versus the consensus of $31.50 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• Delta Air Lines stock climbs on earnings beat and strong guidance
• AeroVironment sets fiscal year 2030 revenue target of $3.5B-$4B
• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance